C4 Therapeutics, Inc.
CCCC · Nasdaq · United States
Share price · CCCC
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CCCC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Oct 2026+10.9%
Nothing announced by CCCC that day or the session before.
- 2 Oct 2026-6.1%
Nothing announced by CCCC that day or the session before.
- 30 Sep 2026+6.4%
Nothing announced by CCCC that day or the session before.
- 29 May 2026+19.4%
Nothing announced by CCCC that day or the session before.
- 13 May 2026+16.1%
- 10 Mar 2026-13.1%
- 9 Mar 2026+18.1%
- 2 Mar 2026+17.4%
Nothing announced by CCCC that day or the session before.
- 25 Feb 2026+15.9%
Nothing announced by CCCC that day or the session before.
- 19 Feb 2026+11.0%
Nothing announced by CCCC that day or the session before.
Share of unusual movement by asset
For each asset, the share of CCCC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Cemsidomideevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 20% |
| Sessions with no dated event | — | 80% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Cereblon E3 ubiquitin-ligaseSmall molecule | Multiple Myeloma | |
| Phase 1 | EGFR L858R (including T790M/C797S resistant mutants)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2030 (1)
March 2030 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $8.5M | $25M | $36M+ $173M short-term inv. | $22M-$26M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $6.6M | $24M | $82M+ $222M short-term inv. | $24M-$1.6M operating cash flow | report ↗ |
| 2026-Q1 | $6.2M | $25M | $65M+ $207M short-term inv. | $25M-$30M operating cash flow | report ↗ |
| 2025-Q3 | $11M | $26M | $62M+ $141M short-term inv. | $32M-$31M operating cash flow | report ↗ |
| 2025-Q2 | $6.5M | $26M | $82M+ $145M short-term inv. | $26M-$12M operating cash flow | report ↗ |
| 2025-Q1 | $7.2M | $27M | $55M+ $183M short-term inv. | $26M-$33M operating cash flow | report ↗ |
| 2024-Q3 | $15M | $32M | $63M+ $225M short-term inv. | $25M-$24M operating cash flow | report ↗ |
| 2024-Q2 | $12M | $24M | $77M+ $223M short-term inv. | $18M-$5.0M operating cash flow | report ↗ |
| 2024-Q1 | $3.0M | $23M | $93M+ $210M short-term inv. | $28M-$18M operating cash flow | report ↗ |
| 2023-Q3 | $11M | $28M | $64M+ $185M short-term inv. | $27M-$31M operating cash flow | report ↗ |
| 2023-Q2 | $2.7M | $30M | $48M+ $242M short-term inv. | $36M-$19M operating cash flow | report ↗ |
| 2023-Q1 | $3.8M | $29M | $53M+ $256M short-term inv. | $35M-$33M operating cash flow | report ↗ |
| 2022-Q3 | $6.8M | $30M | $53M+ $264M short-term inv. | $32M-$28M operating cash flow | report ↗ |
| 2022-Q2 | $14M | $31M | $61M+ $250M short-term inv. | $27M-$22M operating cash flow | report ↗ |
| 2022-Q1 | $7.7M | $26M | $49M+ $245M short-term inv. | $32M-$27M operating cash flow | report ↗ |
| 2021-Q3 | $8.5M | $24M | $164M+ $239M short-term inv. | $25M-$18M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $36M | $104M | $78M+ $223M short-term inv. | $26M-$99M operating cash flow | report ↗ |
C4 Therapeutics, Inc. reported revenue of $35.95M, up 1.0% YoY, R&D spend of $104.24M, down 5.8% YoY, cash and equivalents of $78.05M, and a net loss of $104.99M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $36M | $111M | $59M+ $212M short-term inv. | $26M-$65M operating cash flow | report ↗ |
| 2023-FY | $21M | $118M | $130M+ $155M short-term inv. | $33M-$107M operating cash flow | report ↗ |
| 2022-FY | $31M | $118M | $33M+ $307M short-term inv. | $32M-$106M operating cash flow | report ↗ |
| 2021-FY | $46M | $95M | $79M+ $233M short-term inv. | $21M-$87M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($145K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-12 | Adams Kendra · Chief Financial Officer | Open-market sale | 45,173 | $2.71 | $122K | Form 4 |
| 2026-10-01 | GROGAN DONNA ROY · director | Award / grant | 4,618 | $3.14 | $15K | Form 4 |
| 2026-10-01 | Anderson Kenneth Carl · director | Award / grant | 3,662 | $3.14 | $11K | Form 4 |
| 2026-09-18 | Adams Kendra · Chief Financial Officer | Option exercise | 6,250 | — | — | Form 4 |
| 2026-09-18 | Adams Kendra · Chief Financial Officer | Tax withholding | 2,775 | $3.39 | $9K | Form 4 |
| 2026-07-10 | REYNO LEONARD · Chief Medical Officer | Option exercise | 15,325 | — | — | Form 4 |
| 2026-07-10 | REYNO LEONARD · Chief Medical Officer | Tax withholding | 7,397 | $4.06 | $30K | Form 4 |
| 2026-07-01 | GROGAN DONNA ROY · director | Award / grant | 3,341 | $4.34 | $14K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 123 reporting institutions held 84.9M shares ($216.9M, 76.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | MORGAN STANLEY | 9,072,400 | $23.9M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 8,000,000 | $21.0M |
| 3 | Bain Capital Life Sciences Investors, LLC | 7,171,910 | $18.9M |
| 4 | Lynx1 Capital Management LP | 6,998,902 | $18.4M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3,861,852 | $10.2M |
| 6 | Soleus Capital Management, L.P. | 3,803,942 | $10.0M |
| 7 | TWO SIGMA INVESTMENTS, LP | 3,035,634 | $8.0M |
| 8 | WASATCH ADVISORS LP | 2,961,761 | $7.8M |
| 9 | JPMORGAN CHASE & CO | 3,223,054 | $7.6M |
| 10 | CITADEL ADVISORS LLC | 2,511,015 | $6.6M |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 2,461,815 | $6.5M |
| 12 | GOLDMAN SACHS GROUP INC | 2,387,378 | $6.3M |
| 13 | BANK OF AMERICA CORP /DE/ | 2,359,241 | $6.2M |
| 14 | Squadron Capital Management LLC | 2,250,000 | $5.9M |
| 15 | BlackRock, Inc. | 2,048,526 | $5.4M |